Literature DB >> 11549683

Pharmacogenetic polymorphisms of the AR and metabolism and susceptibility to hormone-induced azoospermia.

B Yu1, D J Handelsman.   

Abstract

Clinical trials of hormonal male contraceptive regimens have identified a consistent population polymorphism in susceptibility to hormone-induced azoospermia. Using identical hormonal regimens, fewer men of European origin (approximately two thirds) become azoospermic compared with Asian men who virtually all become azoospermic. This variation within and between populations remains unexplained. To investigate pharmacogenetic differences in androgen metabolism or action that might explain variable susceptibility to hormonal-induced azoospermia, we studied single nucleotide polymorphism in the CYP3A4 gene, which encodes the major hepatic T-inactivating enzyme, and CAG and GGC triplet repeats in the AR gene in 75 Australian volunteers participating in a male hormonal contraceptive study and 106 population controls. These men were classified into groups according to whether 6 months of weekly T enanthate injections produced azoospermia (n = 54), near-azoospermia (n = 7), and nonazoospermia (n = 14). Mutagenically differentiated PCR was designed to identify A/G variants in the promoter region of the CYP3A4 gene. Fluorescent-labeled DNA fragments containing either CAG or GGC repeats were amplified from the genomic DNA, and their sizes were determined based on the capillary electrophoresis. The G allele of CYP3A4 gene was absent from the nonazoospermia and near-azoospermia groups, but overall this single nucleotide polymorphism distribution did not differ significantly between men in the azoospermia group or population controls. There were no significant differences in distribution of CAG and GGC triplet repeats among three groups or between them and the population controls based on the maximum likelihood estimate of the odds ratio and CLUMP II analyses. These results suggested that neither genetic polymorphisms in the AR gene (CAG and GGC repeats) nor that in hepatic androgen metabolism (CYP3A4 A/G variant) were the major contributors to the within-population variations in susceptibility to T-induced azoospermia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11549683     DOI: 10.1210/jcem.86.9.7793

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

Review 1.  Does ethnicity matter in male hormonal contraceptive efficacy?

Authors:  Niloufar Ilani; Peter Y Liu; Ronald S Swerdloff; Christina Wang
Journal:  Asian J Androl       Date:  2011-02-14       Impact factor: 3.285

2.  The Clinical and Polynucleotide Repeat Expansion Analysis of ATXN2, NOP56, AR and C9orf72 in Patients With ALS From Mainland China.

Authors:  Xiaorong Hou; Wanzhen Li; Pan Liu; Zhen Liu; Yanchun Yuan; Jie Ni; Lu Shen; Beisha Tang; Junling Wang
Journal:  Front Neurol       Date:  2022-05-06       Impact factor: 4.086

Review 3.  Progress and prospects in male hormonal contraception.

Authors:  John K Amory
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2008-06       Impact factor: 3.243

Review 4.  Advances in male contraception.

Authors:  Stephanie T Page; John K Amory; William J Bremner
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

Review 5.  Male hormonal contraception: looking back and moving forward.

Authors:  M Y Roth; S T Page; W J Bremner
Journal:  Andrology       Date:  2015-10-09       Impact factor: 3.842

6.  Genetic Association Between Androgen Receptor Gene CAG Repeat Length Polymorphism and Male Infertility: A Meta-Analysis.

Authors:  Bihui Pan; Rui Li; Yao Chen; Qiuqin Tang; Wei Wu; Liping Chen; Chuncheng Lu; Feng Pan; Hongjuan Ding; Yankai Xia; Lingqing Hu; Daozhen Chen; Jiahao Sha; Xinru Wang
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

7.  Male contraception.

Authors:  Vivek Mathew; Ganapathi Bantwal
Journal:  Indian J Endocrinol Metab       Date:  2012-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.